NYSE: BMY

Price$54.78 Change +0.19 %Change +0.35% Volume: 26,862,929 20 minute delay February 21, 2017

Cancer Survivors Need More Efficient Integrated Long-Term Care and Stronger Policies Across Healthcare, Advocacy and the Workplace, New Research Concludes

02/02/2017

The Economist Intelligence Unit Examines the Growing Worldwide Trend of Cancer Survivorship in a Bristol-Myers Squibb-sponsored research initiative

PRINCETON, N.J.--(BUSINESS WIRE)-- As more patients are living longer with cancer, multi-stakeholder-driven changes are required to improve integrated, or coordinated, care that addresses the range of their long-term needs, according to a new Bristol-Myers Squibb-sponsored global research initiative developed by The Economist Intelligence Unit (EIU) titled Global Cancer Survivorship: The Need for Integrated Care.

The research, released today in the lead up to World Cancer Day 2017 (February 4), reveals challenges with providing cancer services that are physically and financially accessible, and characterizes policy and practice changes necessary to deliver integrated care for cancer survivors in the long-term.

“According to a new global research initiative, greater engagement from healthcare providers, employers, patient advocates and policymakers is needed to drive effective strategies and improve efficiencies in long-term, integrated cancer care that addresses the quality of survival at all stages,” said Emmanuel Blin, Chief Strategy Officer, Bristol-Myers Squibb. “The multi-pronged research explores several concepts, including the value of cancer survivorship, and introduces powerful ideas to support the cancer community in the long-term.”

Cancer survivorship, the process of living with, through and beyond cancer, is a positive global public health trend expected to grow unprecedentedly in the next few decades because of improved diagnostics and treatments. Cancers are among the leading causes of illness and death worldwide, with approximately 14 million newly diagnosed patients and 8.2 million cancer-related deaths annually, according to the World Health Organization (WHO). Some 32.6 million people were five-year cancer survivors in 2012, the most recent data available, but the rates of survivors vary by cancer and geographies. WHO reports more developed regions have survival rates of about 1,619 people per 100,000 population, but in less developed regions, the rate falls to about 376 people.

Global Cancer Survivorship: The Need for Integrated Care is a robust initiative, resulting in a series of publications featuring actionable insights for several stakeholders. Key research outputs, available at http://cancersurvivorship.eiu.com/, include:

  • Evidence-based approaches to address the future of cancer care via a series of scenarios, modeled after The Economist’s ‘World If’ supplement, explore the complexities of access to cancer care and value-based healthcare, offering diverse approaches to making these scenarios tomorrow’s reality.
  • Approaches to strengthen workplace support for those affected by cancer. Results from a survey of 500 senior executives in 20 countries show that some organizations are introducing innovative policies for employees when newly diagnosed with cancer and under treatment, as well as those surviving with these illnesses as chronic conditions or who serve as caregivers for others with cancer. However, more action is needed. Of the companies surveyed, 60% offer workplace adjustments to employees living with cancer, and 54% offer compassionate leave beyond nationally set limits to employees caring for a family member with cancer. However, a comprehensive explanation of return-to-work options is only offered by 44% of surveyed employers, for example.
  • Best practices to address challenges faced by patients, primary-care doctors and policymakers via seamless, more efficient support networks that yield improved patient outcomes. Improving organizational aspects of cancer care, such as care pathways that map treatment, including rehabilitation and aftercare, with structured and systematic communication and coordination between care providers, must also account for individual experiences and strong policy partnership across government and non-government sectors.

Additional research to be published later in 2017 will explore cancer survivor policies and experiences in six countries, Brazil, France, Germany, Italy, Japan and the United States, and takes an in-depth look into the challenges cancer survivors face in these geographies.

About the Research Initiative

Bristol-Myers Squibb sponsored the Global Cancer Survivorship: The Need for Integrated Care research initiative conducted by The Economist Intelligence Unit (EIU), a world leader in global business intelligence, and the business-to-business arm of The Economist Group, which publishes The Economist newspaper. The global project examines the needs of cancer survivors and explores how governments, businesses, healthcare professionals and patient advocates support survivors, while probing additional changes they may need to make in the future.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

Source: Bristol-Myers Squibb

Media:

Bristol-Myers Squibb

Audrey Abernathy, 919-605-4521

audrey.abernathy@bms.com

Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available from the Securities and Exchange Commission, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the company’s website at www.bms.com.